| Title: |
Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma |
| Authors: |
Barr, Paul M.; Smith, Stephen D.; Roschewski, Mark J.; O’Brien, Susan M.; Sharman, Jeff P.; Melear, Jason M.; Patel, Priti; Calvo, Roser; Yang, Helen; Spurgeon, Stephen E. |
| Contributors: |
Acerta Pharma, a member of the AstraZeneca group; Acerta Pharma |
| Source: |
Leukemia & Lymphoma ; volume 63, issue 7, page 1728-1732 ; ISSN 1042-8194 1029-2403 |
| Publisher Information: |
Informa UK Limited |
| Publication Year: |
2022 |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1080/10428194.2022.2043301 |
| Availability: |
https://doi.org/10.1080/10428194.2022.2043301; https://www.tandfonline.com/doi/pdf/10.1080/10428194.2022.2043301 |
| Rights: |
http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| Accession Number: |
edsbas.32AB308 |
| Database: |
BASE |